<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03941080</url>
  </required_header>
  <id_info>
    <org_study_id>201900296</org_study_id>
    <nct_id>NCT03941080</nct_id>
  </id_info>
  <brief_title>Gut Microbiome Dynamics in Metastasized or Irresectable Colorectal Cancer</brief_title>
  <acronym>GIMICC</acronym>
  <official_title>Gut Microbiome Dynamics in Metastasized or Irresectable Colorectal Cancer: Initiating a Prospective Multicenter Cohort (GIMICC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the characteristics and alterations of the gut microbiome during chemotherapy
      for metastasized or irresectable CRC are studied, as well as the relation between the gut
      microbiome and the effects of chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although systemic treatment for metastasized or irresectable colorectal cancer (CRC) is
      becoming increasingly effective, overall survival is still poor and side effects of current
      treatment modalities are substantial. There is an urgent need for novel therapies, and in
      addition, better predictive tools are needed to select the right drug to the right patient.
      New data suggest that modulation of the microbiome of the gut might provide opportunities to
      increase anti-tumor efficacy of immunotherapy. Whereas the relation between the gut
      microbiome and immunotherapy is intensively studied, the relation between the gut microbiome
      and efficacy of conventional chemotherapy is unknown. A better understanding of the
      composition, function and dynamics of the gut microbiome before and during chemotherapy might
      help to identify factors that can be influenced during the treatment of patients with
      metastasized or irresectable CRC.

      Therefore, in this study the characteristics and alterations of the gut microbiome during
      chemotherapy for metastasized or irresectable CRC are studied, as well as the relation
      between the gut microbiome and the effects of chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prediction of response to conventional systemic anti-tumor therapy conventional systemic anti-tumor therapy for metastatic or irresectable colorectal cancer</measure>
    <time_frame>2 years</time_frame>
    <description>To determine which bacteria species in the microbiome predict response to conventional systemic anti-tumor therapy according to RECIST v1.1 for metastatic or irresectable colorectal cancer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prediction of serious side effects to conventional systemic anti-tumor therapy for metastatic or irresectable colorectal cancer</measure>
    <time_frame>2 years</time_frame>
    <description>To determine which bacteria strains in the microbiome predict serious side effects (grade 3/4 according to CTCAE v4.03) to conventional systemic anti-tumor therapy for metastatic or irresectable colorectal cancer</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Colorectal Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>GIMICC</arm_group_label>
    <description>Adult patients with newly diagnosed metastasized or irresectable CRC with an indication for standard palliative systemic anti-tumor treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>fecal sample</intervention_name>
    <description>patients will collect fecal samples at home prior to treatment and at 3 months after start of treatment at the time of response evaluation using a standard stool-collection-kit.</description>
    <arm_group_label>GIMICC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>questionnaire</intervention_name>
    <description>At the day of stool sampling, patients fill out a brief questionnaire about established factors that can change the microbiome such concurrent use of antibiotics and proton pump inhibitors.</description>
    <arm_group_label>GIMICC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>4 tubes of blood are collected prior to treatment and at 3 months after start of treatment at the time of response evaluation and sent to the UMCG for storage.</description>
    <arm_group_label>GIMICC</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Fecal sample and blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who present in the hospitals of the North Netherlands Colorectal Cancer Network.
        The participating hospitals together cover 10% of the Dutch population. Given that 13.000
        patients yearly are diagnosed with colorectal cancer of which one third will develop
        metastatic or irresectable disease (www.iknl.nl), in the hospitals participating in this
        study 400 potential patients will present. Taking into account that about 50% do not fulfil
        in- and exclusion criteria or will refuse to participate, about 200 patients per year are
        expected to be included.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Patients with histologically confirmed CRC with an indication for palliative systemic
             anti-tumor therapy (ANY combination of chemotherapy with/without anti-VEGF of
             anti-EGFR therapy)

          -  Measurable disease according to RECIST v1.1.

          -  Stored pathological specimens available

          -  Life expectancy ≥ 12 weeks

          -  Signed Informed Consent Form

          -  Ability to comply with protocol

        Exclusion Criteria:

          -  Previous (neo)adjuvant chemotherapy &lt; 6 months

          -  Uncontrolled inflammatory bowel disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. J. de Haan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>J. J. de Haan, MD, PhD</last_name>
    <phone>+31 50 3612821</phone>
    <email>j.j.de.haan@umcg.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>D. J. de Groot, MD, PhD</last_name>
    <phone>+31 50 361 2821</phone>
    <email>d.j.a.de.groot@umcg.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Wilhelmina Ziekenhuis</name>
      <address>
        <city>Assen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>P. Nieboer, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Nij Smellinghe</name>
      <address>
        <city>Drachten</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>G. Bouma, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Treant Zorggroep</name>
      <address>
        <city>Emmen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>C. Oldenhuis, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>L. Mekenkamp, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>J. J. de Haan, MD, PhD</last_name>
      <phone>+31 50 361 6161</phone>
      <email>j.j.de.haan@umcg.nl</email>
    </contact>
    <contact_backup>
      <last_name>D. J. de Groot, MD, PhD</last_name>
      <phone>+31 50 361 2821</phone>
      <email>d.j.a.de.groot@umcg.nl</email>
    </contact_backup>
    <investigator>
      <last_name>J. J. de Haan, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Martini Ziekenhuis</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>J. van Rooijen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saxenburgh Groep</name>
      <address>
        <city>Hardenberg</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>R. Blankenburgh, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tjongerschans Ziekenhuis</name>
      <address>
        <city>Heerenveen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>H. Bos, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>B. Rikhof, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ommelander Ziekenhuis Groep</name>
      <address>
        <city>Scheemda</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>B. Poppema, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Antonius Zorggroep</name>
      <address>
        <city>Sneek</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>G. Veldhuis, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 29, 2019</study_first_submitted>
  <study_first_submitted_qc>May 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2019</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Dr. J.J. de Haan</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>colorectal cancer</keyword>
  <keyword>gut microbiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

